Genfit S.A. (GNFTF)
OTCMKTS · Delayed Price · Currency is USD
3.720
+0.440 (13.41%)
At close: Jul 25, 2025
Genfit Revenue
In the year 2024, Genfit had annual revenue of 70.69M EUR with 105.01% growth. Genfit had revenue of 9.59M in the half year ending December 31, 2024, a decrease of -32.01%.
Revenue
70.69M EUR
Revenue Growth
+105.01%
P/S Ratio
2.89
Revenue / Employee
392.73K EUR
Employees
180
Market Cap
211.60M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 70.69M | 36.21M | 105.01% |
Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tian'an Technology Group | 2.12M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |
Genfit News
- 2 months ago - Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewsWire
- 3 months ago - GENFIT: June 17, 2025 Combined Shareholders Meeting Results - GlobeNewsWire
- 4 months ago - Genfit S.A. reports Q1 results - Seeking Alpha
- 4 months ago - GENFIT Reports First Quarter 2025 Financial Information - GlobeNewsWire
- 4 months ago - GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy - GlobeNewsWire
- 4 months ago - GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) - GlobeNewsWire
- 4 months ago - GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents - GlobeNewsWire
- 4 months ago - GENFIT to Present Latest ACLF Research at EASL Congress 2025 - GlobeNewsWire